Asymmetric upside here on a biotech stock that's been absolutely battered. Runway for pharmaceutical approvals are ripe and Dec 20 could launch this.
RJM11.eth
Asymmetric upside here on a biotech stock that's been absolutely battered. Runway for pharmaceutical approvals are ripe and Dec 20 could launch this.